ArticleBMC nephrology2025
Decrease in Escherichia-Shigella in the gut microbiota of ESKD patients undergoing maintenance hemodialysis.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Prevention of Intestinal Inflammation and Gut Dysbiosis by Prebiotic Grape Seed Flour in Mice with DSS-Induced Colitis.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Dual-Phase Immunomodulation by the Bovine β-Casein Peptide KEMPFPK: Insights into Potential TLR Interaction and Gut Microbiota-Mediated Effects.Foods (Basel, Switzerland) · 2026Article
- Article
- Remodeling of Gut Microbial Networks After Sulforaphane Supplementation in Patients with Chronic Kidney Disease.Life (Basel, Switzerland) · 2025Article
- Alterations in gut-kidney axis indicators and TMAO-related biomarkers in elderly patients with hypertensive nephropathy.Frontiers in medicine · 2025Article
- Tirzepatide modulates gut microbiota homeostasis to protect against diabetic kidney disease.Frontiers in molecular biosciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundGut dysbiosis is thought to be involved in the pathogenesis and progression of chronic kidney disease and end-stage kidney disease (ESKD). However, differences in the composition and function of gut microbiota in hemodialysis patients are not consistently concluded.
methodsA total of 20 patients receiving maintenance hemodialysis (MHD) treatment at the Blood Purification Center of Bethune International Peace Hospital from March 2021 to December 2022 were included based on the inclusion criteria. Additionally, 20 healthy volunteers matched for age, gender, and body mass index were recruited from the Health Examination Center as the healthy control (HC) group. The structure of the gut microbiota community in the study subjects was analyzed using second-generation high-throughput sequencing technology based on 16S rRNA and amplicon sequence variants (ASV) analysis.
resultsThere were significant differences in gut microbial communities between the two groups. At the genus level, significant differences were found in 19 genera. Among them, Escherichia-Shigella, Lachnospira, Parasutterella, [Ruminococcus]-torques-group, Butyricicoccus, and Streptococcus were significantly decreased, while Phascolarctobacterium, Ruminococcaceae-UBA1819, Erysipelotrichaceae-UCG-003, Flavonifractor, and Erysipelatoclostridium were significantly increased in MHD patients. In particular, the abnormal decrease in the abundance of p-Proteobacteria.c-Gammaproteobacteria.o-Enterobacterales.f-Enterobacteriaceae.g-Escherichia-Shigella might be a significant characteristic of gut microbiota in MHD patients.
conclusionThe decreased abundance of Escherichia-Shigella is a signature gut microbiota alteration in patients with ESKD undergoing MHD, and Escherichia-Shigella may represent a key bacterial group warranting exploration in the field of hemodialysis. The dysbiosis of gut microbiota holds promise as a therapeutic target and biomarker for the diagnosis and treatment of MHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.